html

The Canine IMHA Journey

A practical treatment timeline explaining what may happen after a dog is diagnosed with immune-mediated haemolytic anaemia, from emergency stabilisation through monitoring, medication changes and possible remission.

Canine IMHA
Species scope notice This timeline focuses on canine IMHA, which has the strongest published evidence base. Cats and horses may require different diagnostic approaches, medication choices, monitoring schedules and prognostic discussions. Please use the feline and equine sections of IMHA Toolkit for species-specific information.

Every dog is different, but many cases follow a broadly similar pattern from diagnosis through stabilisation, treatment, medication tapering and, hopefully, long-term remission. This timeline explains what commonly happens at each stage.

Phase 1

Day 1–2: Diagnosis and emergency stabilisation

Highest concern

This is often the most frightening stage for owners.

Your dog may be admitted to hospital for urgent assessment, oxygen support, intravenous fluids, blood testing and, in some cases, a blood transfusion. Treatment commonly begins quickly because IMHA can deteriorate rapidly.

Your veterinary team may discuss immunosuppressive medication, clot-prevention treatment, transfusion decisions and monitoring for complications.

Owner focus: Ask your vet what is being monitored, whether clot prevention is being used or considered, and what warning signs would require emergency attention.

Clinical focus: confirm haemolysis, assess severity, stabilise the patient and consider early thrombotic risk.

  • Typical early investigations may include CBC/PCV, blood smear review, saline agglutination testing, biochemistry, bilirubin assessment and urinalysis.
  • Immunosuppressive treatment is commonly initiated once IMHA is considered likely, with dose selection guided by current consensus guidance, formulary advice and patient-specific risks.
  • Thromboprophylaxis should be actively considered in canine IMHA unless there is a clear contraindication, because thromboembolic disease is a recognised major complication.
Clinical note: This page summarises published guidance and does not replace case-specific clinical judgement, referral advice or current formulary verification.
Phase 2

Days 3–7: Early treatment response

Critical monitoring

Treatment has started, but your dog may not be stable yet.

The red blood cell level may still fluctuate, and your dog may need repeated blood checks. Some dogs remain in hospital; others may come home with strict monitoring instructions.

Clotting complications remain a serious concern during this period, even if the anaemia appears to be improving.

Emergency warning signs: sudden heavy breathing, collapse, weakness, blue or purple gums, marked distress, coughing blood, severe abdominal pain or sudden inability to walk should be treated as urgent.

Clinical focus: assess haematological response, transfusion need, thrombotic risk and early treatment tolerance.

  • Serial PCV or haematocrit monitoring is commonly used to assess stability.
  • Worsening anaemia or poor early response may prompt clinical review of the treatment plan, including dosing, additional immunosuppression or supportive care.
  • Monitor for respiratory change, perfusion deficits, neurological signs, limb pain, abdominal pain or other features that could suggest thromboembolic complications.
Practical point: Clear communication between the veterinary team and the owner is important during this window, particularly around monitoring, medication instructions and emergency warning signs.
Phase 3

Weeks 2–4: Early stability and medication side effects

Stability check

This is the stage where many owners start to notice the burden of medication.

High-dose steroids can cause intense hunger, thirst, panting, restlessness, increased urination, muscle loss and a pot-bellied appearance. These effects can be distressing, but they are common.

Your dog may seem brighter, but that does not mean the disease is controlled enough for medication to be reduced.

Home care: Do not restrict water. Keep a medication chart. Ask your vet how often blood tests are needed and what signs should trigger an urgent call.

Clinical focus: assess stability, adverse effects and whether future tapering criteria are being approached.

  • Repeat CBC/PCV and relevant biochemistry are commonly used to monitor response and medication tolerance.
  • Do not assume clinical improvement alone equals remission; active haemolysis markers and haematological stability remain important.
  • If steroid toxicity is significant, consider whether adjunct immunosuppression or specialist advice is appropriate.
Tapering caution: Any dose reduction should be gradual and supported by objective evidence of stability.
Phase 4

Months 2–6: Gradual tapering and relapse monitoring

Step-down phase

This is usually a slow, careful process.

Your vet may gradually reduce medication if your dog’s blood results remain stable. Relapse can occur if treatment is reduced too quickly or if the disease is not fully controlled.

Many dogs still need regular checks during this period, even when they look much better at home.

Owner rule: Never alter, skip or stop IMHA medication without veterinary instruction. Ask when the next blood test is due after each medication change.

Clinical focus: structured tapering, relapse surveillance and screening for treatment complications.

  • Medication reductions should generally be staged and guided by repeat haematology and clinical assessment.
  • Continue monitoring for steroid-related complications, infection, gastrointestinal signs and biochemical changes.
  • Consider urine culture where clinically appropriate, particularly in dogs receiving prolonged immunosuppressive treatment.
  • Thromboprophylaxis duration should be reviewed in light of current guidance, ongoing haemolysis, mobility, comorbidities and bleeding risk.
Documentation point: Record the tapering rationale, owner instructions and the planned review interval at each dose change.
Phase 5

Beyond 6 months: Remission and long-term follow-up

Possible remission

Many dogs can return to a happy, normal life.

Some dogs are eventually weaned off medication. Others may need long-term low-dose treatment or periodic monitoring. Your vet may recommend ongoing checks even after your dog appears well.

Remission does not mean owners should panic about every minor change, but it does mean knowing what warning signs matter.

Long-term care: Keep a record of previous IMHA treatment, medication reactions and blood results. Tell any future vet that your dog has a history of IMHA.

Clinical focus: validate remission, reduce relapse risk and establish a long-term monitoring plan.

  • Remission assessment should be based on stable haematology, absence of active haemolysis and clinical wellbeing.
  • Where multiple immunosuppressive drugs have been used, staged withdrawal is generally preferable to multiple simultaneous changes.
  • Long-term follow-up may include periodic CBC and biochemistry, especially in dogs with previous relapse or prolonged treatment.
Clinical note: Vaccination, surgery and other immune-relevant decisions should be considered individually in dogs with a history of IMHA.

Evidence note: This timeline is an educational overview based on publicly available veterinary literature and consensus guidance, including the ACVIM consensus statement on treatment of immune-mediated haemolytic anaemia in dogs. It is not a substitute for veterinary examination, case-specific clinical judgement, specialist advice or current formulary verification.